Jason Hoitt
Net Worth
Last updated:
What is Jason Hoitt net worth?
The estimated net worth of Mr. Jason Hoitt is at least $3,001,655 as of 10 Feb 2023. He has earned $45,005 from insider trading and has received compensation worth at least $2,956,650 in Provention Bio, Inc..
What is the salary of Jason Hoitt?
Mr. Jason Hoitt salary is $591,330 per year as Chief Commercial Officer in Provention Bio, Inc..
How old is Jason Hoitt?
Mr. Jason Hoitt is 47 years old, born in 1978.
What stocks does Jason Hoitt currently own?
As insider, Mr. Jason Hoitt owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Provention Bio, Inc. (PRVB) | Chief Commercial Officer | 4,500 | $0 | $0 |
What does Provention Bio, Inc. do?
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Jason Hoitt insider trading
Provention Bio, Inc.
Mr. Jason Hoitt has made only one insider trade between 2020-2023, according to the Form 4 filled with the SEC. He sold 4,500 units of PRVB stock worth $45,005 on 10 Feb 2023.
As of 10 Feb 2023 he still owns at least 4,500 units of PRVB stock.
Provention Bio key executives
Provention Bio, Inc. executives and other stock owners filed with the SEC:
- Dr. Eleanor L. Ramos (69) Chief Medical Officer
- Dr. Francisco Leon M.D., Ph.D. (53) Co-Founder & Chief Scientific Officer
- Mr. Andrew T. Drechsler (53) Special Advisor
- Mr. Ashleigh W. Palmer B.Sc., M.B.A. (62) Co-Founder, Pres, Chief Executive Officer & Director
- Mr. Jason Hoitt (47) Chief Commercial Officer